APLS Apellis Pharmaceuticals
- 28.740
- -0.090-0.31%
Apellis Pharmaceuticals News
Apellis Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Francois Cedric
Apellis Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.1%)
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Watson David O.
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dunlop A. Sinclair
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dunlop A. Sinclair
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Chopas James George
Apellis Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Chopas James George
Apellis Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer DeLong Mark Jeffrey
Apellis Pharmaceuticals | 8-K: Current report
Apellis Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dunlop A. Sinclair
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dunlop A. Sinclair
Apellis Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Apellis Pharmaceuticals | 8-K: Current report
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Deschatelets Pascal
Apellis Pharmaceuticals | 8-K: Current report
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Deschatelets Pascal
Analysis
Price Target
No Data
No Data
